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Abstract: The potential to induce therapeutic angiogenesis through gene transfer has engen-
dered much excitement as a possible treatment for tissue ischemia. After 10 years of clinical 
experimentation, however, it now appears clear that several crucial issues are still to be resolved 
prior to achieving clinical success. These include the understanding of whether functional blood 
vessels might arise as a result of the delivery of a single angiogenic factor or require more 
complex cytokine combinations, the identiﬁ  cation of the proper timing of therapeutic gene 
expression and, most notably, the development of more efﬁ  cacious gene delivery tools. Viral 
vectors based on the adeno-associated virus (AAV) appear particularly suitable to address the 
last requirement, since they display a speciﬁ  c tropism for skeletal muscle cells and cardiomyo-
cytes, and drive expression of the therapeutic genes in these cells for indeﬁ  nite periods of time. 
In this review, I discuss the current applications of gene therapy for cardiovascular disorders, 
with particular attention to the possible improvements in the technologies involved in virus-
mediated gene transfer.
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Despite the remarkable progresses made over the last several years in early diagnosis 
and prevention, cardiovascular disorders still represent the leading cause of morbid-
ity and mortality in the industrialized world and a rising concern in most developing 
countries (Srinath Reddy et al 2005). In Europe alone, over 600,000 deaths per year are 
registered due to myocardial infarction or arise as a consequence of ischemic cardio-
myopathy, with an incidence of 1:6 in men and 1:17 in women (http://www.heartstats.
org). The current approaches of medical (trombolysis) or surgical (angioplasty and 
aorto-coronary bypass) revascularization have signiﬁ  cantly modiﬁ  ed the natural history 
of ischemic cardiomyopathy. However, the limitations of these interventions and their 
relatively poor efﬁ  cacy in the long term render the progression toward heart failure 
inevitable in several patients. Therefore, novel approaches for therapeutic intervention 
are clearly needed. Similar considerations also apply to critical limb ischemia, which 
is estimated to develop in 500–1,000 individuals per million per year.
Over the last several years, the possibility of exploiting gene delivery for the pro-
duction of therapeutic factors as a new strategy to treat cardiovascular disease has been 
supported by the success in pre-clinical experimentation in small and large animal 
models of human disease. As opposed to other gene therapy applications, at least three 
considerations support the relative feasibility of the gene therapy approach in the cardio-
vascular system. First, both the heart and selected vascular districts are easily accessible 
by using the same devices and techniques that are commonly used by interventional 
cardiology. Gene delivery is thus local and, in most instances, speciﬁ  c cell targeting is 
not required. Second, basic research on the molecular and cellular pathways of cardiac 
and vascular metabolism has provided an impressive list of genes encoding factors that International Journal of Nanomedicine 2007:2(4) 528
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support cardiac function or trigger new blood vessel formation; 
for several of these genes, preclinical proof of the efﬁ  cacy of 
their overexpression has already been obtained. Last, most 
gene therapy applications in the cardiovascular ﬁ  eld will be 
successful even if achieving relatively modest results when 
compared to the more demanding goals that are required, for 
example, by gene therapy for hereditary disorders. Even a 
positive modulation of cardiac function, a signiﬁ  cant decrease 
in arterial restenosis, or a slowing down of progression toward 
heart failure would represent excellent clinical endpoints from 
which to build more ambitious applications.
This review discusses the current applications of gene 
therapy for the induction of new blood vessel formation in isch-
emic tissues. I will pay particular attention to the technologies 
involved in virus-mediated gene transfer to the myocardium 
and to the arterial wall, given the pivotal role played by issues 
concerning delivery in determining the outcome of any gene 
therapy procedure.
Vectors for cardiovascular gene 
transfer
The success of a gene therapy application depends on three 
major parameters, namely the choice of an appropriate 
therapeutic gene, the delivery of this gene to a sufﬁ  cient 
number of cells and the achievement of appropriate levels 
of gene expression. One of the major hurdles that have so 
far hampered a wider range of gene therapy applications 
has been the lack of an ideal vector, capable of fulﬁ  lling the 
above requirements and, at the same time, of providing an 
acceptable safety proﬁ  le. Table 1 reports the gene delivery 
procedures that are currently available for gene therapy in 
the cardiovascular arena.
The plasma membrane of mammalian cells is a highly 
selective barrier that normally precludes the entry of 
polypeptides and other macromolecules, including highly 
charged nucleic acids. In contrast to this general rule, 
for reasons that are still unclear, skeletal muscle cells 
and cardiomyocytes are indeed capable of spontaneously 
uptaking small quantities of naked DNA. This property has 
been at the basis of diverse gene therapy experimentation 
based on plasmid DNA injection to promote therapeutic 
angiogenesis, which will be discussed later. However, the 
very low efﬁ  ciency at which DNA internalization occurs 
(at least 2 orders of magnitude lower than virus-mediated 
gene delivery) and the limited period of time during which 
the transgene is expressed (usually less than 10–14 days) 
still represent major obstacles that have so far prevented 
the broad success of this approach.
A potentially interesting and novel way to improve the 
delivery of plasmid DNA into both endothelial cells and 
– after disruption of endothelial cell junctions – the underly-
ing muscle cells is the utilization of ultrasounds, either alone 
or in combination with ecographic contrast media based on 
gas microbubbles (Lawrie et al 1999; Amabile et al 2001; 
Chen et al 2003). When the latter are used, their rupture 
induced by ultrasounds determines an acoustic cavitation 
event that creates physical pores in the cell plasma mem-
brane. Through these pores, naked DNA can penetrate into 
the cell’s cytoplasm. Although promising (Ay et al 2001; 
Danialou et al 2002; Miura et al 2002; Taniyama et al 2002; 
Huber et al 2003), the outcome of this procedure still appears 
quite variable and further optimization is required before it 
reaches the clinic.
Currently, viral vectors based on recombinant adenovirus 
(Ad) or adeno-associated virus (AAV) are the most successful 
and extensively used tools to deliver genes in the cardiovas-
cular system (Guzman et al 1993; Fisher et al 1997). These 
two vectors share a few similar features, such as the ability to 
transduce a variety of quiescent cell types after in vivo injec-
tion, including skeletal muscle cells and cardiomyotyes, and 
amenability to easy laboratory manipulation.
Adenoviral vectors
Ad vectors based on serotype 5 have been by far the most 
commonly used vectors for delivery to the cardiovascular 
system. These vectors can accommodate large inserts, medi-
ate transient but high levels of protein expression, and can 
be easily produced at high titers, all remarkable properties 
in the gene therapy scenario (St George 2003). A schematic 
representation of the genetic organization of wild type 
adenovirus and of the vectors derived from this virus is 
shown in Figure 1. A ﬁ  rst generation of vectors contained the 
therapeutic genes cloned in order to substitute the early E1A 
and E1B genes, the E1 region being the only portion of the 
adenoviral genome absolutely required for viral replication. 
These defective adenoviruses have been used extensively in a 
number of gene therapy clinical trials, including experimenta-
tion in the cardiovascular ﬁ  eld (see below). Although very 
efﬁ  cient in terms of transduction and transgene expression 
in the infected cells, the in vivo application of these vectors 
is notably limited by their strong immunogenicity and by 
the stimulation of a potent inﬂ  ammatory response (Yang et 
al 1996). Major safety concerns about a wider use of these 
vectors have been raised by the death of a young patient 
recruited in a gene therapy trial for the treatment of a rare 
metabolic disorder (OCT deﬁ  ciency). The lethal event was International Journal of Nanomedicine 2007:2(4) 529
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most probably due to a systemic inﬂ  ammatory response to 
the vector triggered by the expression of several wild type 
adenoviral genes by the transduced cells (Lehrman 1999).
In order to limit these highly undesirable effects, a 
second generation adenoviral vector was developed, in 
which other viral genes (in particular, E3 and E4) had 
been deleted. These second generation vectors are better 
tolerated in terms of immune response and persist longer 
in the injected animals, at least in some speciﬁ  c tissues. 
However, for reasons that are still to be understood, the 
levels of transgene expression from these vectors appears 
quite unsatisfactory (Qian et al 2001).
Finally, a third generation adenoviral vector consists of 
the so called “gutless” or helper-dependent vectors, which 
contain the therapeutic gene and the two repeated regula-
tory regions at the 3' and 5' of the wild type genome, which 
also include the signals required for packaging the genome 
into viral particles. The production of these gutless viruses 
requires co-infection of the producing cells by a ﬁ  rst gen-
eration adenoviral vector carrying a modiﬁ  cation in the 5' 
repeated region. Through this, the Cre recombinase produced 
by the infected cells determines the deletion of the packaging 
signal of the helper construct, which is ﬂ  anked by two LoxP 
sites (Mitani et al 1995; Parks et al 1996). These vectors are 
efﬁ  cient and very well tolerated in vivo; in addition, they 
permit cloning of large DNA inserts, thus opening the way 
to the possibility of transferring large cDNAs or even entire 
genomic regions including their normal regulatory genetic 
elements. However, their production is quite cumbersome 
and the efﬁ  ciency of puriﬁ  cation of the vector from the helper 
virus particles is rather inefﬁ  cient, thus still preventing broad 
clinical application.
Adeno-associated virus (AAV) vectors
A constantly growing number of pre-clinical gene therapy 
studies exploit vectors based on AAV, a small non-
enveloped, single-stranded (ss) DNA virus with a diameter 
of 18–25 nm, which belongs to the Parvoviridae family 
and is classiﬁ  ed in the Dependovirus genus. Members of 
this genus are widely diffuse in nature: well over 100 AAV 
variants have so far been isolated from primate sources, and 
new serotypes are continuously discovered. All serotypes 
share a similar structure, genome size and genetic organiza-
tion. Over the last few years, viral vectors based on AAV 
have gained increasing popularity due to several favorable 
characteristics, including the high efﬁ  ciency of transduction 
of post-mitotic tissues such as muscle, heart, brain and retina 
and the long-term persistence of transgene expression in the 
Table 1 Gene transfer procedures for cardiovascular gene therapy applications
Strategy Method  Advantages  Disadvantages
Naked DNA (plasmids  Direct injection  Easiness of production and use  Modest efﬁ  ciency
and oligonucleotides)      Transitory effect
Lipofection  Liposomes  Easiness of production and use  Modest efﬁ  ciency
  Cationic lipids    Transitory effects
 Complexes
 liposomes/proteins
Viral vectors  Adenoviral vectors  High multiplicity of infection  Transient transduction
    High levels of transgene expression  Activation of a powerful antiviral
    Highly concentrated vector preparations  inﬂ  ammatory and immune response
    High cloning capacity
    Infection of both quiescent and
   proliferating  cells
    Broad cell tropism
  AAV vectors  Non pathogenic  Relatively limited cloning capacity (<5 kb)
   Speciﬁ  c tropism for skeletal and cardiac  Absence of packaging cell lines
    myocytes and artery smooth muscle cells
    Highly concentrated vector preparations
    High multiplicity of infection
    Transduction of quiescent cells
   Not  inﬂ  ammatory and not immunogenic
    Trangene expression persisting indeﬁ  nitely
   in  vivo
Physical methods  Electroporation  Relatively easy of set up (for the  Low efﬁ  ciency
   skeletal  muscle)
Physical methods  Ultrasounds  Exploits established clinical procedures  Still not optimizedInternational Journal of Nanomedicine 2007:2(4) 530
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absence of inﬂ  ammation or immune response (Favre et al 
2001). The wild type, 4.7 kb long AAV genome contains 
two open reading frames, corresponding to the rep and cap 
genes encoding for the replicative and capsid proteins of the 
virus, respectively (Figure 1). Through the use of two dif-
ferent promoters and the alternative inclusion of one exon, 
the rep gene gives rise to four protein isoforms (rep78, 68, 
52 and 40). Three different products (VP1, VP2, VP3) are 
also generated from the cap gene after the alternative usage 
of three different translation start sites and of a common 
polyadenylation signal. The coding region of AAV is ﬂ  anked 
by two 145 bp interted terminal repeats (ITRs), which are   
complementary within the ﬁ  rst 125 bp and form a T-shaped 
hairpin at both ends of the genome. This palindromic 
sequence is the only cis-acting element required for all the 
major functions of AAV (viral DNA replication, assembly 
of the viral particles, integration/excision from the host 
genome) and is the only sequence of viral origin present in 
the vector DNA.
The life cycle of wild type AAV strictly depends on the 
presence or absence of host cell coinfection with a helper 
virus. Under non-permissive conditions (ie, without a helper 
virus), the AAV genome mainly integrates into a speciﬁ  c 
region (AAVS1) of human chromosome 19q13.3 (Kotin 
et al 1992; Linden et al 1996; Dutheil et al 2000), where it 
establishes a latent infection for indeﬁ  nite periods of time. 
This represents the only characterized instance of site-speciﬁ  c 
integration of a virus in a mammalian cell; the exploitation 
of this event would permit the safe insertion of exogenous 
genes into the human genome, a highly desirable goal in the 
gene therapy ﬁ  eld. In this respect, however, it needs to be 
pointed out that site-speciﬁ  c integration is entirely dependent 
on the function of the AAV Rep proteins. Since the rep gene 
is removed from the vector DNA – mainly because its unregu-
lated expression is toxic to the infected cells (see Marcello 
et al (2000) and citations therein) – the current generation 
of AAV vectors persists inside non-dividing cells mainly 
as extrachromosomal, concatemerized DNA (Schnepp et al 
2005); if the vector genome integrates, it does so in a random 
manner (Miller et al 2005).
The characteristics of the AAV life cycle, including its 
defectiveness and ability to persist in infected cells as a latent 
viral genome, suggested early on that this virus could be an 
excellent tool for in vivo gene transfer (Tratschin et al 1984). 
Since the AAV genome cloned into a plasmid is still infec-
tious and able to produce viral particles, any exogenous gene 
(less than 4.5 kb in length) can, in theory, be placed within 
the two 145 bp ITRs to obtain a circular backbone suitable 
for vector production. Unlike other delivery systems that have 
evolved over several generations, the original composition 
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Figure 1 Schematic representation of the genetic organization of AAV and adenovirus (left side) and of the respective vectors. The location at which the therapeutic gene 
cassette (promoter+gene+polyadenylation site) is inserted is indicated. TR, Terminal repeat sequence.International Journal of Nanomedicine 2007:2(4) 531
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of the AAV vector plasmid (a transgene expression cassette 
ﬂ  anked by the two ITRs) is essentially the same as in the 
current version. The traditional method for rAAV production 
was based on co-transfection of the vector plasmid together 
with a second plasmid, supplementing the Rep and Cap 
gene functions, into Ad helper-infected cells (usually HeLa 
or HEK293 cells); more recently, adenovirus co-infection 
has been substituted by the co-transfection of a plasmid also 
expressing a few adenoviral genes, which provide the helper 
functions (Grimm et al 1998) (Figure 2).
Therapeutic angiogenesis
The possibility to exploit viral vectors to deliver genes to 
the myocardium and the skeletal muscle at high efﬁ  ciency 
permits the development of novel therapeutic strategies for 
the treatment of cardiac and limb ischemia. Ischemia refers 
to a lack of oxygen due to inadequate perfusion, which 
results from an imbalance between oxygen supply and 
demand. The most common cause of myocardial ischemia 
is the atherosclerosis of epicardial coronary arteries. Slowly 
developing, high-grade coronary artery stenosis does not 
usually precipitate acute infarction, because of the progres-
sive development of a rich collateral network. Myocardial 
infarction generally occurs when there is an abrupt decrease 
in coronary blood ﬂ  ow, following the thrombotic occlusion 
of a coronary artery, previously narrowed by atherosclerosis. 
This event is associated with the almost instantaneous failure 
of normal muscle contraction and relaxation. The events 
following myocardial infarction often have a devastating 
impact on the patient’s conditions, principally because 
of the irreversible death of the cardiomyocytes and their 
substitution over time by a scar of akinetic ﬁ  brous tissue. 
The extent of the infarction depends on the duration and the 
severity of the perfusion defect. However, the entity of the 
myocardial injury is also modulated by a number of factors, 
including development of a functional collateral circulation, 
medical therapy and ischemic preconditioning. Beyond scar 
contraction, progressive ventricular remodelling can further 
reduce cardiac function in the weeks following the initial 
event (Pfeffer et al 1991).
Most of the currently available therapies – for instance 
angioplasty and thrombolysis – can signiﬁ  cantly relieve the 
cause of the infarction, notably improving the prognosis of 
patients. Conversely, after the occurrence of the irreversible 
injury, no medication or procedure has so far shown efﬁ  cacy 
in restoring adequate blood supply and replacing the ﬁ  brous 
tissue with new contractile ﬁ  bres. Consequently, most of the 
patients experiencing a myocardial infarction inexorably 
progress toward heart failure.
The possibility to promote the neovascularization of 
ischemic tissues is a highly ambitious objective, rendered 
possible by the identiﬁ  cation, over the last 15 years, of several 
cytokines and growth factors able to physiologically activate 
an angiogeneic process. Traditionally, new blood vessel 
formation in the adult life occurs through capillary sprouting 
from pre-existing vessels (Figure 3). The process is initiated 
by the metabolic activation, proliferation and migration of 
endothelial cells, concomitant with vast remodeling of the 
extracellular matrix (reviewed in Risau 1997). In physi-
ological conditions, the main regulator of angiogenesis is 
hypoxia. In conditions of low oxygen tension, the cellular 
transcription factor HIF-1 (Hypoxia Inducible Factor –1) 
is post-translationally stabilized and activates the expres-
sion of a vast series of genes, among which the vascular 
endothelial growth factor (VEGF) and its receptors, which 
are required for all phases of angiogenesis (Liu et al 1995). 
The VEGF family is composed of at least six members 
(VEGF-A, B, C, D, E and PlGF – Placental Growth Factor), 
AAV vector
plasmid
AAV vector
Therapeutic gene AAV genes
Helper
plasmid
Ad helper genes
HEK 293 cells
CaPO4  transfection
Cell lysis
Recombinant
Purification of viral
vector by cesium
chloride gradient
centrifugation rAAV
Collect and dialyze fractions
Titration by real time PCR
Assay for transgene expression
Figure 2 Production of AAV vectors. A plasmid containing the therapeutic gene 
cassette (promoter+gene+polyadenylation site) cloned between the AAV terminal 
repeats is co-transfected into epithelial HEK293 cells together with a plasmid con-
taining the rep and cap AAV genes and some genes from adenovirus that provide 
helper function. After 48 hours, cells are lysed and recombinant vector particles are 
puriﬁ  ed by cesium chloride gradient centrifugation. Fractions are collected from 
the gradient and the number of particles containing viral genomes are quantiﬁ  ed by 
real-time PCR.International Journal of Nanomedicine 2007:2(4) 532
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with different isoforms arising from alternative splicing 
(Ferrara 1999). The best characterized family member is 
VEGF-A, the action of which is mediated by its recep-
tors VEGFR-1/Flt-1 and VEGFR-2/KDR/Flk-1 present in 
endothelial cells (Carmeliet and Collen 1999; Neufeld et al 
1999). It has become increasingly apparent that these main 
receptors act in concert with several other co-receptors, 
belonging to the integrin, cadherin, neuropilin and ephrin 
receptor families; the expression of these co-receptors on 
endothelial cells potentiates or modulates the proliferative 
and chemotactic effect of VEGF (Soker et al 1998; Gale 
and Yancopoulos 1999; Bussolino et al 2001). In addition, 
different members of the ephrin and semaphorin (neuropilin 
ligands) families, originally identiﬁ  ed as guides of axonal 
growth, have recently been shown to exert similar roles in 
nascent vasculature, where they act in concert with VEGF 
(Gale et al 2001).
Besides endothelial cell sprouting, functional new blood 
vessel formation also requires other factors that act at later 
time points to promote vessel maturation. Among these, 
an essential role is played by the angiopoietins, and, in 
particular, by angiopoietin-1 (Ang1), which, by interacting 
with the Tie2 receptor on the endothelial surface, reduces 
the permeability of the newly formed vasculature (Asahara 
et al 1998; Davis and Yancopoulos 1999; Thurston et al 
2000; Arsic et al 2003). Different molecular mechanisms 
support the favorable effects of Ang1 on vessel maturation 
and function, including the recruitment of pericytes (Dumont 
et al 1994; Suri et al 1996) or mesenchymal precursors 
(Metheny-Barlow et al 2004), the strengthening of intercel-
lular junctions between adjacent endothelial cells (Gamble 
et al 2000) and the direct interference with the intracellular 
signaling-pathways responsible for VEGF-triggered vascular 
leakiness (Jho et al 2005).
In addition to VEGF, several other growth factors are 
able to activate endothelial cells and promote the angiogenic 
response. Among these factors, much interest has been 
engendered by some members of the ﬁ  broblast growth factor 
family (FGF) (Battler et al 1993). By interacting with differ-
ent ubiquitous receptors, these factors are able to stimulate, 
on one side, endothelial cell proliferation, while, on the other 
side, the secretion of proteases that are essential for extracel-
lular matrix degradation and cellular migration in the initial 
phases of the angiogenic process (Giordano et al 1996). It is 
estimated that there are 23 structurally similar forms of FGF. 
The speciﬁ  c role of these different FGF family members 
during normal angiogenesis in vivo and their relevance in 
different physiological and pathological conditions still needs 
to be thoroughly addressed. FGF1, 2, 4 and 5 have been used 
in angiogenic studies and no signiﬁ  cant differences in efﬁ  cacy 
have been detected (Yla-Herttuala and Alitalo 2003).
Gene therapy clinical trials
to induce therapeutic angiogenesis
After the identiﬁ  cation of VEGF and FGF as powerful induc-
ers of angiogenesis, various clinical trials were conducted 
with the purpose of evaluating the effect of these factors when 
delivered as recombinant proteins (in particular, TRAFFIC 
and FIRST, which assessed the effect of FGF2 on peripheral 
(Lederman et al 2002) and coronary artery (Simons et al 
2002) disease respectively, and VIVA, which evaluated 
rhVEGF in patients with coronary heart disease (Henry et al 
2003). Quite unexpectedly, and in contrast to the brilliant 
results obtained by the same formulations in different animal 
models of acute or progressive ischemia (Sato et al 2000), 
the administration of these recombinant proteins produced 
only modest or no result at all in the treated patients. The 
negative outcome of this experimentation might be attributed 
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Figure 3 Sprouting angiogenesis. In adult organisms, angiogenesis is initiated upon the metabolic activation, proliferation and mobilization of endothelial cells lining pre-
existing vessels. This process is triggered by various angiogenic cytokines, including VEGF and FGF2 and is accompanied by the destabilization of the extracellular matrix by 
matrix metalloproteases (MMP). At later time points, the newly formed capillary matures by the acquisition of pericytes and smooth muscle cells to form a new medial layer. 
The maturation process requires the action of several other cytokines, among which the angiopoietins, ephrins and semaphorins play a major role.International Journal of Nanomedicine 2007:2(4) 533
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to a number of different reasons, among which the very short 
half-life of these cytokines in vivo and the de-sensitization of 
chronic ischemic tissues to growth factor treatment.
Injection of naked plasmid DNA
One applicable way to overcome the poor success of recom-
binant protein administration is the delivery of the cDNAs 
encoding for these factors, which, in principle, should 
ensure the prolonged expression of the desired cytokine 
by the ischemic tissues in vivo. Indeed, this approach has 
initially engendered great enthusiasm after the vectors 
expressing the VEGF and FGF2 cDNAs have been success-
fully used in various pre-clinical models of myocardial and 
limb ischemia in small and large animals (Faries et al 2000; 
Khan et al 2002). Clinical experimentation in patients began 
in the mid '90s, by identifying patients with critical limb 
ischemia who had exhausted all conventional options for 
revascularization (Isner et al 1996). The treatment consisted 
in the injection of a plasmid coding for the 165 amino acid 
isoform of VEGF-A. The success of this treatment was 
evaluated by angiography and nuclear magnetic resonance, 
revealing the formation of new collateral vessels and a 
signiﬁ  cant perfusion improvement in the VEGF-treated 
group (Baumgartner et al 1998). The only reported major 
side effect was the occurrence of a remarkable edema of 
the leg, probably due to the increase in vessel permeability 
caused by VEGF (Baumgartner et al 2000). A series of over 
20 clinical trials followed, which entailed the injection of 
naked plasmids encoding VEGF to the myocardium through 
a mini left anterior thoracotomy (Losordo et al 1998; Symes 
et al 1999; Vale et al 2000; Fortuin et al 2003; Reilly et al 
2005), or by a transendocardial approach using a NOGA 
catheter (Losordo et al 2002). Most of these procedures were 
well tolerated, with few major adverse cardiac events and 
without complications directly related to gene expression. 
The results of these early studies performed by naked DNA 
injection should be interpreted with caution, considering 
their uncontrolled, open-label design and the signiﬁ  cant 
sham or placebo effect observed by any intervention in 
patients with coronary artery disease. Indeed, a double-
blinded, placebo-controlled experimentation performed in 
Europe a few years later (the Euroinject One trial) failed 
to show any signiﬁ  cant difference between injection of 
a plasmid encoding VEGF165 and placebo in patients 
(Gyongyosi et al 2005; Kastrup et al 2005).
Other currently ongoing clinical trials, also based on 
naked plasmid DNA gene transfer, take advantage of a 
plasmid encoding FGF1 (aFGF) fused to a heterologous 
secretion signal under the control of a constitutive strong 
promoter (NV1FGF). A phase I, multicenter, open label 
experimentation has already been conducted in patients 
with severe peripheral vascular disease by intramuscular 
injection of increasing and repeated doses to patients with 
unreconstructible, end-stage peripheral arterial occlusive 
disease (Comerota et al 2002). Following these results, a 
Phase IIb, double-blind, randomized, placebo-controlled 
clinical trial has been recently conducted in 6 European 
countries in patients with critical limb ischemia at high 
risk of amputation. Despite the fact that no improvement in 
wound healing was seen, the results showed that this new 
treatment signiﬁ  cantly reduced the risk of amputation and 
might thus lead to lower mortality rates in patients. This 
treatment will be further evaluated in a larger, Phase III 
experimentation, which is scheduled to begin in the second 
quarter of 2006.
Finally, two additional ongoing trials exploit naked DNA 
gene transfer in patients with peripheral artery disease. The 
ﬁ  rst is aimed at delivering the hepatocyte growth factor 
(HGF) cDNA, a cytokine that, besides mitogenic potential 
on liver cells, also plays an important, multifaceted role in 
angiogenesis, organogenesis in embryonic development, as 
well as in the regeneration of tissues and organs damaged by 
a various forms of injury (Morishita et al 2004). The second 
experimentation is based on the administration of a plasmid 
encoding the angiomatrix protein Del-1 (developmentally 
regulated endothelial locus 1), a unique αvβ3 integrin ligand 
that is normally produced by endothelial cells and mediates 
cell attachment, migration, and activation of cytoplasmic 
signaling molecules in focal contacts (Rajagopalan et al 
2004). The latter experimentation is carried out by mixing 
the Del-1 plasmid with Poloxamer-188, a surfactant polymer 
with antithrombotic and hemorheologic properties, which is 
frequently used in the pharmaceutical industry as an emulsi-
ﬁ  er or solubilizer.
Adenoviral vectors
Despite the relative ease of production and administration 
of naked plasmid DNA, the clinical success of this approach 
has been, so far, generally poor, and the therapeutic beneﬁ  t 
that has to be expected from the ongoing experimentation is 
thus limited. This is mainly due to the very low efﬁ  ciency 
of tissue transfection currently attainable by simple naked 
DNA injection and the relatively short period of transgene 
expression. Given these limitations, other clinical trials have 
exploited ﬁ  rst generation Ad vectors as a mean to deliver 
various therapeutic genes.International Journal of Nanomedicine 2007:2(4) 534
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The angiogenic gene therapy (AGENT) studies have 
addresses the safety and efficacy of the non-surgical, 
intracoronary injection of an Ad vector expressing FGF4 
(Ad5FGF4) in patients with stable angina. In particular, 
AGENT has compared the effects of 5 ascending Ad5FGF4 
doses (Grines et al 2002), while AGENT2 has been the ﬁ  rst 
phase I/IIa, randomized, double-blind, placebo-controlled 
trial of therapeutic angiogenesis, comparing the effect of 
a single intracoronary injection of 1 × 1010 Ad5FGF4 viral 
particles (Grines et al 2003). The AGENT trials established 
that intracoronary administration of Ad5FGF4 could be 
performed with reasonable safety in patients with coronary 
artery disease, and that a one-time dose could provide an 
anti-ischemic effect up to 12 weeks of evaluation. Further 
appraisal of the efﬁ  cacy and safety of Ad5FGF-4 has then 
been planned in two simultaneous phase IIb/III multicenter, 
randomized, double-blind, placebo-controlled pivotal trials in 
the United States and the European Union, with the designed 
enrollment of approximately 1,000 treated subjects. Unfor-
tunately, however, an interim analysis of the preliminary 
data from one of these trials has clearly indicated that the 
trials, as designed, would provide insufﬁ  cient evidence of 
efﬁ  cacy. Therefore, further recruitment was stopped at the 
beginning of 2004.
Another series of clinical experimentation was based 
on the delivery of a defective Ad expressing the VEGF121 
cDNA under the control of the CMV enhancer/promoter 
(Ad(GV)VEGF121.10). The RAVE trial was a phase II, 
double-blind, placebo-controlled study designed to test the 
efﬁ  cacy and safety of intramuscular delivery of this vector 
to the lower extremities of 105 subjects with unilateral 
peripheral artery obstructive disease. This study showed 
that a single unilateral intramuscular administration of 
AdVEGF121 was not associated with improved exercise 
performance or quality of life, and did not support further 
experimentation (Rajagopalan, Mohler et al 2003). The 
same vector has also been tested in two different phase 
I trials in patients with coronary artery disease entailing 
direct intramyocardial injection during coronary bypass 
artery grafting (CABG) (Rosengart et al 1999). Sixteen 
patients, who could not be completely revascularized by 
CABG, received the vector as intramyocardial injections 
in conjunction with CABG. Another 15, who were not 
candidates for traditional mechanical revascularization 
and who had severe angina despite being on maximal 
medical treatment, received the adenovirial vector as 
10–30 intramyocardial injections administered via a mini-
thoracotomy. Similar to the peripheral vascular disease 
population, vector administration was well tolerated 
without any consistent drug-related side effects. There were 
indications towards improvement in angina symptoms, 
quality of life and treadmill times as well as in myocardial 
perfusion scans. However, as with the peripheral vascular 
disease population, these results are difﬁ  cult to interpret 
in the context of an open-labeled, non-controlled trial. 
Nevertheless, the suggested therapeutic activity along 
with the safety proﬁ  le, justiﬁ  ed activation of a phase 
II randomized prospective, proof-of-concept' trial in 
‘no-option’ patients. This phase II trial, called REVASC, 
involved 20 sites in North America; 71 patients with severe 
coronary artery disease were enrolled. The preliminary 
results showed signiﬁ  cant improvements in both cardiac 
function and quality of life (Stewart 2002). Currently, a 
multicenter, randomized, double-blind placebo-controlled 
study is ongoing in Denmark, Israel and United Kingdom 
to evaluate the efﬁ  cacy of Ad-VEGF121 in patients with 
advanced coronary artery disease and moderate to severe 
angina despite optimal medical treatment, and who are not 
amenable to percutaneous coronary revascularization or 
bypass grafting. The end-point of this study will include 
functional measures (exercise capability), physiological 
measures (SPECT) and symptomatic/quality of life 
measures.
Two trials have assessed the efﬁ  ciency of an adenovirus 
expressing the 165 amino acid isoform of VEGF (VEGF-
Adv) or of a plasmid expressing the same gene delivered in 
a liposome formulation (VEGF-P/L) injected intra-arterially 
after percutaneous transluminal angioplasty in patients with 
peripheral (Makinen et al 2002) and coronary artery disease 
(Hedman et al 2003) – the KAT trial. Both the adenovirus 
and plasmid formulations were reported to improve the vas-
cularity of the treated limbs 3 months after therapy and to 
enhance myocardial perfusion in the coronary heart disease 
patients 6 months after therapy.
Finally, a phase I clinical trial evaluating an adenovirus 
vector expressing HIF-1α/VP16 (Ad2HIF-1α/VP16) for 
the treatment of peripheral arterial disease has recently 
been completed. Although the ﬁ  nal results of this initial 
trial have not been yet published, preliminary data on the 
28 participants appear promising (Rajagopalan, Deitcher 
et al 2003). The hypoxia-inducible factor (HIF-1) is a 
trimeric master transcription factor controlling the expres-
sion of several genes involved in a variety of processes in 
endothelial cells, including glucose metabolism, erythro-
poiesis, regulation of vascular tone, and cell proliferation 
and survival (Wenger and Gassmann 1997). Among the International Journal of Nanomedicine 2007:2(4) 535
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genes that are activated, several exert powerful angiogenic 
activity, including VEGF; as neovascularization results 
from the complex interplay of a variety of factors, an 
upstream regulatory protein such as HIF-1 could potentially 
be more effective as a therapeutic agent than any single 
pro-angiogenic factor. Intracellular oxygen concentration 
regulates HIF-1 activity by inﬂ  uencing both stability and 
transcriptional activity of the HIF-1α subunit of HIF-1 
(Poellinger and Johnson 2004); under normoxic conditions, 
HIF-1α is targeted for ubiquitination and proteosomal 
degradation. A constitutively-active version of HIF-1α 
was generated by replacing the C-terminus of the protein, 
including its oxygen-dependent and endogenous transac-
tivation domains, with the strong transactivation domain 
from the herpes virus VP16 protein. Administration of 
plasmid DNA encoding HIF-1α/VP16 has been shown to 
increase blood ﬂ  ow in animal models of both cardiac and 
peripheral ischemic disease (Vincent et al 2000; Shyu et al 
2002). In a similar approach, constitutively-active, modiﬁ  ed 
versions of the native HIF-1α  protein have been reported to 
promote angiogenesis in the hindlimbs of mice and rabbits 
(Pajusola et al 2005; Patel et al 2005). After the success-
ful demonstration of the safety of the Ad2HIF-1α /VP16 
delivery, a phase II trial has recently been started in patients 
with peripheral artery disease. This is a placebo-controlled 
study that will enroll up to 200 patients at approximately 35 
medical centers in the United States and Europe.
Table 2 reports a summary of the above described clinical 
experimentation.
Improved strategies to induce 
efﬁ  cient therapeutic angiogenesis
What are the main lessons learned from these clinical trials? 
Despite over 10 years of clinical experimentation, it is very 
clear that gene therapy for ischemic heart and peripheral 
artery disease is still in its infancy. An initial series of at least 
seven cohort studies, in which patients have been followed 
up to 2 years post-injection, reported highly positive results 
(Losordo et al 1998; Rosengart et al 1999; Symes et al 1999; 
Vale et al 2000; Fortuin et al 2003). These studies, however, 
essentially suffered from a lack of control groups. In contrast, 
the overall outcome of the randomized trials have been much 
more disappointing (Yla-Herttuala and Alitalo 2003). While 
the deﬁ  nitive results of ongoing experimentation has to be 
carefully evaluated before a deﬁ  nitive conclusion is drawn, 
it nevertheless appears that novel vectors and improved 
delivery methods are needed before deﬁ  nitive clinical suc-
cess might be met.
Improvement of gene delivery
Irrespective of the therapeutic gene involved, it appears 
that the efﬁ  ciency of gene delivery currently represents one 
of the major limitations that still hamper clinical success. 
Plasmid DNA delivery is simple and fraught with major 
Table 2 Major gene therapy clinical trials
Vector Gene  Disorder  Route  Reference
Naked DNA  VEGF-A 165 aa  PAOD  Intramuscular  Baumgartner et al (1998)
plasmid    CAD  Intramyocardial  Losordo et al (1998); Symes et al
        through minithoracotomy  (1999); Vale et al (2000); Fortuin et al
          (2003); Reilly et al (2005)
        Transendocardial  Losordo et al (2002)
        catheter-based  Gyongyosi et al (2005); Kastrup et al
           (2005) (EUROINJECT 1)
    FGF1 (NV1FGF)  PAOD  Intramuscular  Comerota et al (2002)
    HGF  PAOD  Intramuscular  Morishita et al (2004)
    Del-1  PAOD  Intramuscular  Rajagopalan et al (2004)
Plasmid DNA/liposome  VEGF-A 165 aa  PAOD  Intraarterial after PTA  Makinen et al (2002)
      CAD  Intraarterial after PTA  Hedman et al (2003) (KAT)
Adenoviral vectors  FGF4  CAD  Intracoronary  Grines et al (2002); Grines et al (2003)
         (AGENT)
    VEGF-A 121 aa  PAOD  Intramuscular  Rajagopalan, Mohler et al (2003) (RAVE)
      CAD  Intramyocardial during CABG  Rosengart et al (1999); Stewart (2002)
        or via minithoracotomy  (REVASC)
    VEGF-A 165 aa  PAOD  Intraarterial after PTA  Makinen et al (2002)
      CAD  Intraarterial after PTA  Hedman et al (2003) (KAT)
   HIF1α/VP16  PAOD  Intramuscular  Rajagopalan, Deitcher et al (2003)
Abbreviations: CAD, coronary artery disease; PAOD, peripheral artery occlusive disease; PTA, percutaneous transluminal angioplasty; CABG, coronary artery bypass 
grafting.International Journal of Nanomedicine 2007:2(4) 536
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safety concerns; however, the efﬁ  ciency of uptake of naked 
DNA by muscle and cardiac cells, even if surprisingly higher 
than with most other cell types, is still very poor. Despite 
preparations of plasmids injected in quantities to the order 
of hundred micrograms or milligrams, the levels of the DNA 
that is internalized by the cells remain orders of magnitude 
lower than those obtained using viral vectors. In addition, 
most preclinical investigations have revealed that measurable 
levels of gene expression are maintained only for the ﬁ  rst 
couple of weeks after injection. This condition might not be 
sufﬁ  cient to exert an angiogenic stimulus able to generate a 
stable neovasculature.
Other clinical trials have been conducted using ﬁ  rst 
generation adenoviral vectors, which carry deletions in the 
E1 and, in a few instances, in the E3 genes. These vectors 
are excellent tools for gene transfer given the efﬁ  cacy at 
which they both infect cells and express genes. However, 
these vectors are fraught with several problems, mainly due 
to the strong inﬂ  ammatory and immune response they elicit. 
This essentially reduces the vector dose that can be injected, 
prevents the possibility of vector re-injection, and limits the 
expression of transgene to 1–2 weeks after transduction, after 
which the host’s immune system eliminates the transduced 
cells (Gilgenkrantz et al 1995). A completely new genera-
tion of adenoviral vectors devoid of viral genes, which are 
still infectious but less immunogenic, would deﬁ  nitely be 
desirable. However, after almost 10 years of development 
of gutless adenoviral vectors (Mitani et al 1995; Parks et al 
1996), the problems intrinsic to the development of these 
vectors are still not solved.
Given the current concerns on safety and performance of 
lentiviral vectors, the only viral vector system that, at present, 
appears suitable for gene therapy of cardiovascular disorders 
is the one based on AAV. As outlined above, these vectors 
display a number of appealing features for gene transfer in 
the heart and in the skeletal muscle. Among these features 
are the lack of relevant immunogenicity, the absence of an 
inﬂ  ammatory response at the site of injection, the possibil-
ity of obtaining relatively pure vector preparations at high 
titres, the capacity of transducing cells at high multiplicity 
of infection – which allows mixing of different prepara-
tions and thus therapy with gene cocktails – . In addition, 
even more relevant characteristics are the speciﬁ  c – and still 
unexplained – tropism for muscle cells and cardiomyocytes, 
and the ability of these vectors to drive expression of the 
therapeutic gene they carry for indeﬁ  nite periods of time in 
these post-mitotic tissues. Given these features, it might be 
reasonably expected that these vectors will play a central role 
in the clinical cardiovascular gene therapy experimentation 
in the near future.
Cell targeting
Strictly related to the issue of gene delivery for cardiovas-
cular disorders is the problem of conferring upon vectors 
the property of targeting speciﬁ  c cells. In general, the cur-
rently available methods, including non-viral systems and 
both adenovirus and AAV, have a propensity to transduce 
non-vascular tissues with greater ease than vascular cells, 
thereby limiting their application in cardiovascular disease. 
Two strategies are currently envisaged to improve targeting 
of gene transfer, namely the modiﬁ  cation of the properties 
of the surface proteins of viral vectors (Ad and AAV) and 
the improvement of the currently available non-viral delivery 
methods by the inclusion of proteins conferring targeting 
properties.
Ad serotype 5 virions primarily bind, via the knob domain 
of the virus ﬁ  ber protein, to the coxsackie and adenovirus 
receptor (CAR) (Bergelson et al 1997; Tomko et al 1997). 
Upon CAR binding, a secondary interaction between αvβ3/
αvβ5 integrins and the penton base of the Ad capsid (contain-
ing a RGD motif) occurs that mediates internalization of the 
virion (Wickham et al 1993). In addition, the ﬁ  ber protein 
shaft region makes contact with the cell surface heparan 
sulphate proteoglycans (HSPGs) of the target cell. Thus, 
modiﬁ  cations of the amino acid sequence of the Ad knob 
domain (CAR binding), of the penton base (integrin binding) 
and of the intervening ﬁ  ber shaft (HSPG binding) have been 
conceived as ways to modify Ad serotype 5 tropism in vitro 
and in vivo. These modiﬁ  cations include serotype switching 
by ﬁ  ber swapping among the over 50 natural Ad serotypes 
and insertion of targeting peptides into CAR-ablated vectors 
(reviewed in Baker 2004). The majority of these targeting 
peptides, which mediate attachment of the virus to target 
cells, have been isolated by phage display technology. This 
allows high throughput screening of random peptide librar-
ies expressed on the coat protein of ﬁ  lamentous phage for 
their ability to target selected cell populations, either in vitro 
or in vivo (reviewed Hajitou et al 2006). Over the last few 
years, this technology has generated a wealth of peptides that 
exploit receptor diversity on different cell types, including 
different endothelial cell variants. Although the studies so far 
performed with these targeted Ad vectors are encouraging, 
there is little data to suggests that retargeting will be success-
ful in vivo in terms of efﬁ  ciency of gene transfer.
An alternative, promising strategy to target Ad vectors 
to speciﬁ  c cells is the utilization of a dual-speciﬁ  c antibody, International Journal of Nanomedicine 2007:2(4) 537
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which recognizes and inactivates the vector CAR binding 
domain on one side, while on the other side binds a speciﬁ  c 
cell receptor of interest. In the cardiovascular system, cell-
speciﬁ  c gene delivery has so far been achieved using anti-
bodies against a variety of possible targets, which include 
E-selectin, FGF2 receptor, the extracellular domain of the 
angiotensin converting enzyme (ACE) and the Flt-1 tyrosine 
kinase receptor (reviewed in Baker 2004).
Compared to Ad, the AAV serotype 2 vector capsid is less 
tolerant to modiﬁ  cations, with the exception of a few sites 
in which short amino acid targeting peptides can be safely 
inserted without determining a signiﬁ  cant loss of infectivity 
(reviewed in Flotte and Berns 2005). In the cardiovascular 
system, targeted AAV2 vectors might overcome one of the 
most notable limitations of wild type AAV2, namely its 
inability to transduce vascular endothelial cells. Capsid mod-
eling studies for targeting peptide insertions have originally 
been carried out based on the structure of the homologous 
canine parvovirus (Girod et al 1999) and have subsequently 
taken advantage of the solution of the crystal structure of 
AAV2 (Xie et al 2002). Based on this information, different 
laboratories have recently obtained AAV vectors targeted 
to speciﬁ  c cell types (reviewed in Ding et al. 2005). For 
example, the incorporation of a venous endothelial cell tar-
geting peptide into AAV2 has recently allowed transduction 
of venous (but not arterial) endothelial cells both in vitro and 
invivo (White et al 2004). In this respect, however, it must be 
noted that transduction of endothelial cells by AAV, similar 
to other cell types, is limited not only at the level of virus 
entry into the cells, but also, most importantly, at the levels 
of uncoating (Thomas et al 2004), of transport of the viral 
genome to the nucleus (Ding et al 2005) and of conversion 
of the single-stranded viral genome to double-stranded DNA 
(Ferrari et al 1996).
Over the last few years, more than 100 AAV variants 
have been isolated from primate sources, and new sero-
types are continuously being discovered (Gao et al 2005). 
Each of these variants possesses peculiar characteristics in 
terms of efﬁ  ciency of transduction and tropism for speciﬁ  c 
cell populations in vivo. The primary receptors required 
for transduction for some of these AAV serotypes have 
been identiﬁ  ed (such as sialic acid for AAV4 and AAV5 
(Kaludov et al 2001; Walters et al 2001), including the 
sialo-glycoprotein PDGF-R (Di Pasquale et al 2003)) and 
can thus be associated with the transduction pattern for the 
relevant AAV. In most instances, however, the molecular 
determinants of tropism of these alternate AAV serotypes 
(whether at the level of cell surface receptor or at later steps 
after cell entry) is still unknown. Some of these serotypes 
appear very promising for gene therapy applications in the 
cardiovascular system, among which AAV1 and AAV6 for 
local muscle gene delivery by direct intramuscular injection 
and AAV8 and AAV9 for systemic gene transfer to the muscle 
and the heart (Wang et al 2005; Inagaki et al 2006).
Final remarks
It is worth emphasizing that the gene transfer technologies 
that are being developed should be considered not only for 
their eventual therapeutic applications, but also for their utility 
in basic research. In particular, the peculiar feature of AAV 
vectors to express genes for prolonged periods of time in the 
skeletal muscle and heart in the absence of inﬂ  ammation offers 
a simple and straightforward way to examine gene function 
in adult organisms, thus representing an alternative tool to the 
use of transgenic animals. Moreover, since these vectors infect 
cells at high multiplicity, they also allow the simultaneous 
delivery of several combinations of genes to the same tissue. 
This possibility appears to be of great importance, since it will 
eventually permit the deﬁ  nition of the cytokine cocktail that 
has the greatest efﬁ  cacy in the induction of a new functional 
vascular network, deﬁ  nitely an essential requirement for the 
induction of really “therapeutic” angiogenesis.
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